Discussion
Food is the leading known cause of anaphylactic reactions for children
and adolescents in emergency departments in the United States and
Europe, with geographical variations according to local dietary habits
and food exposures (8). Peanut is not only one of the most common food
trigger, but also one of the commonest trigger in anaphylaxis fatalities
in the UK and USA (7). The authors chose to provide a comparison between
anaphylaxis to peanut and other food triggers, although the different
foods included and analysed as a group represent different entities and
considerably different diseases.
Within the European Anaphylaxis Registry, Western European countries
reported the majority of peanut induced anaphylaxis cases, but the
Registry doesn’t collect data from all over Europe. There was no overlap
between these countries and the ones with the highest reports of food
triggered anaphylaxis, in particular Mediterranean countries like
Greece, Spain and Italy with high frequency of food allergy but not
peanut.
The findings of the European Anaphylaxis Registry support previously
published findings from other multi (MIRABEL) (9)- or single
(Riley)-centred registries (10) that peanut allergy is more common in
pre-school aged boys. These data bases included children with peanut
allergy and/or sensitisation not only cases of peanut induced
anaphylaxis. Similar demographics with predominance of males in younger
age groups was described in several food-induced anaphylaxis studies
(11)(12)(13). The lower median age in the other food subgroup is likely
explained by cow’s milk and egg being the predominant elicitors of
allergic reactions in children in the first two years of life.
Previous milder reactions were more frequent in peanut allergic children
(42%) compared to other food triggers (38%), but there was no
difference for previous anaphylaxis. Sicherer et al. (14) showed that
almost 50% of children experience accidental exposure to peanut within
2 years of their first reaction, proving that avoidance is not enough.
The Riley Registry (10) reported anaphylaxis with second exposures in
33.9% of children, and in 33.3% of children who had anaphylaxis with
first exposure. On a larger scale (38.408 children) Gupta et al. (15)
reports an estimated 42.3% of children with a food allergy to have a
history of at least one severe reaction, and 42% to have at least one
lifetime food allergy-related visit to the emergency department.
The majority of cases had a background of atopy, regardless of the
eliciting food, with similar frequencies for atopic dermatitis, allergic
rhinitis, asthma, and other food allergies/sensitisations to other
studies (9). Eczema was more frequent in children allergic to foods
other than peanut, likely in the younger group of infants and toddlers
with cow’s milk and/or egg allergy, in line with the natural history of
this condition. Asthma was more common in the peanut anaphylaxis cohort.
Leickly et al. (10) reports that children with peanut anaphylaxis were
significantly more likely to have asthma (P < .001) and
other food allergies (P = .04) than those with non-anaphylactic
reactions to peanut.
The prevalence of co-factors in anaphylaxis is reported to be around
30% in adults (16) and 18% in children (17). Our data reports relevant
co-factors more frequently in peanut anaphylaxis (29%) compared to
other food triggers (22%), with physical exercise in the lead. Previous
data from the Registry (17)(6) also reported physical exercise to be the
most frequent co-factor, followed by medication. There is a lack of
published data on other large children anaphylaxis cohorts for
comparison.
Non-prepacked food products were only responsible for one out of three
peanut reactions, but for the majority of the events triggered by other
food. It is likely that other food triggers e.g. egg, milk are more
common ingredients in non-prepacked food compared to peanut. However
peanut was more likely to be listed as an ingredient, and the lower
percentage of unknown data regarding labelling in the peanut cohort
along with the lower consumption of non-prepacked food are hopefully
indicative of a higher compliance to allergen avoidance in this group. A
study on peanut-containing foods with precautionary labelling detected
low levels of peanut in only two out of 38 products (18). Another study
(19) reported detectable amounts of three allergens (peanut, milk and
egg) in 5.3% of products with precautionary labelling and in 1.9% of
products without. These issues still have to be addressed (20).
The interval between exposure and onset of symptoms was less than 10
minutes in the majority of cases, with no difference between peanut and
other food, and with figures similar to previous analysis (21)(6).
Anaphylaxis appeared in a delayed pattern in a very small percentage of
cases, again regardless of the food trigger.
Biphasic reactions were significantly more frequent in peanut
anaphylaxis (10%) versus other food triggers (4%). The latter figure
is in keeping with previous analysis of the children/adolescent cohort
(5%) (6), and also with the NORA report on the mixed paediatric and
adult population (4% in food induced anaphylaxis) (21). Similar (13)
but also lower figures (22) were reported in other multicentre studies
on paediatric anaphylaxis.
A possible link is with the higher frequency of severe anaphylaxis in
the peanut cohort (65% grade III) versus the total children/adolescent
cohort (47%) (6) or the mixed paediatric/adult cohort (38.3%) (21).
However, there was no difference in reaction severity between the
children who experienced a biphasic reaction and the ones who did not.
Age 6 to 9 years was reported as one of five independent predictors for
biphasic reactions (23), not confirmed in our data. Sometimes the
prevalence of biphasic anaphylaxis is difficult to assess, depending on
the time interval of patient observation post anaphylaxis, also symptoms
occurring later might not be recognized as being related to the initial
reaction. A systematic review and meta-analysis on predictors of
biphasic analysis found food triggers to be associated with decreased
risk for biphasic reactions (24).
Only 36% of the peanut anaphylactic reactions and 40% of the reactions
triggered by other food were initially treated by a lay person,
including self-administration of i.m. adrenaline. There was no
statistically significant difference between subgroups regarding
self-administration of i.m. adrenaline, but failure to apply/carry an
adrenaline auto-injector was registered in 44% of peanut anaphylaxis
and in 53% of the cases allergic to other food, which matches the
reports of studies evaluating real-world use of AAI (25). In a
community-based survey uncertainty about the severity of the reaction,
fear of side effects, and difficulties deciding which drugs to use were
identified as reasons for not applying AAIs (26).
Professional emergency treatment was mainly carried out by an emergency
physician. Only 1 in 4 children with peanut anaphylaxis treated by a
healthcare professional received adrenaline as first line treatment,
despite the current guidelines reflecting strong expert opinion, that
classifies i.m. adrenaline as first-line treatment of anaphylaxis (27).
Surprisingly, professional administration of adrenaline (i.m., i.v.,
inhaled) was significantly higher in food anaphylaxis other than peanut
compared to peanut anaphylaxis.
Despite recommendations, second- and third line drugs like
antihistamines, steroids and beta 2-agonists were used as first-line
drugs in the majority of the reactions, similar to other studies.
This supports a previous assertion that adrenaline is under-used in
anaphylaxis treatment. A similar or lower proportion was reported for
children and/or adults in other populations. Data from several cohort
studies show the extent of under-treatment of anaphylaxis and the low
rate of adrenaline use (27). US studies report higher usage of
adrenaline in emergency setting, compared to Europe, with the majority
of paediatric emergency medicine physicians (93.5%) correctly
identifying adrenaline as first line treatment in anaphylaxis, yet only
66.9% choosing the i.m. route (28).
Aiming to evaluate the variation in the Emergency Department (ED) care
of children with anaphylaxis, Michelson et al., 2016 (29) performed a
retrospective cross-sectional study on data from 35 hospitals, on ED
visits with a primary diagnosis of anaphylaxis over a period of 4 years,
in children aged 1 month to 18 years. The least variation regarding
adjunct therapies was observed in the use of H1-antihistamines and
steroids, which were also the most frequent administered drugs. The
study did not assess the frequency of adrenaline administration because
it was assumed it is commonly given prior to hospital arrival.
Second-line treatment was required in less than 25% of professionally
treated children (peanut cohort 24% vs other food cohort 19%), and a
second dose of adrenaline was administered in 5% vs 6% (peanut vs
other food). Recent data from the Registry showed that 3.7% of
professionally managed anaphylaxis received a second dose of adrenaline
(27), with higher figures in a mixed but smaller paediatric/adult cohort
(13%; 18.5% for children only) (30).
Hospitalisation was higher in the peanut cohort, likely due to the
difference in anaphylaxis severity (grade III 65% vs 56%; p=0.001).
Despite the fact that most cases were labelled as severe anaphylaxis,
only 6% required admission to the Intensive Care Unit, and 0.7% had a
fatal outcome.
Overall this data confirmed peanut as one of the major causes of severe,
potentially life-threatening allergic reactions in children in Europe.
Peanut anaphylaxis shows some characteristic features e.g. the presence
of asthma comorbidity and the increased rate of biphasic reactions,
conditions which may even be linked to each other. Clinicians should be
aware of such characteristic findings for peanut allergy and consider
these in the management of peanut anaphylactic patients.
References
1. Motosue MS, Bellolio MF, Van Houten HK, Shah ND, Campbell RL.
Increasing Emergency Department Visits for Anaphylaxis, 2005-2014. J
Allergy Clin Immunol Pract [Internet]. 2017 Jan 1 [cited 2019 Nov
17];5(1):171-175.e3.
2. Turner PJ, Gowland MH, Sharma V, Ierodiakonou D, Harper N, Garcez T,
et al. Increase in anaphylaxis-related hospitalizations but no increase
in fatalities: An analysis of United Kingdom national anaphylaxis data,
1992-2012. J Allergy Clin Immunol. 2015;135(4):956-963.e1.
3. Cannon HE. The economic impact of peanut allergies. Am J Manag Care.
2018;24(19):S428–33.
4. Custovic A. Epidemiology of Allergic Diseases. Middleton’s Allergy
Essentials [Internet]. 2017 Jan 1 [cited 2019 Nov 16];51–72.
5. Greenhawt M, Marsh R, Gilbert H, Sicherer S, DunnGalvin A, Matlock D.
Understanding caregiver goals, benefits, and acceptable risks of peanut
allergy therapies. Ann Allergy, Asthma Immunol [Internet].
2018;121(5):575–9.
6. Grabenhenrich LB, Dölle S, Moneret-Vautrin A, Köhli A, Lange L,
Spindler T, et al. Anaphylaxis in children and adolescents: The European
Anaphylaxis Registry. J Allergy Clin Immunol. 2016;137(4):1128-1137.e1.
7. Turner PJ, Baumert JL, Beyer K, Boyle RJ, Chan CH, Clark AT, et al.
Can we identify patients at risk of life-threatening allergic reactions
to food? Allergy Eur J Allergy Clin Immunol. 2016;71(9):1241–55.
8. Lyons S, Clausen M, Knulst, AC, et al. Prevalence of Food
Sensitization and Food Allergy in Children across Europe. J Allergy Clin
Immunol Pr. 2020;S2213-2198.
9. Deschildre A, Elegbédé CF, Just J, Bruyère O, Van der Brempt X,
Papadopoulos A, et al. Peanut-allergic patients in the MIRABEL survey:
Characteristics, allergists’ dietary advice and lessons from real life.
Clin Exp Allergy. 2016;46(4):610–20.
10. Leickly FE, Kloepfer KM, Slaven JE, Vitalpur G. Peanut Allergy: An
Epidemiologic Analysis of a Large Database. J Pediatr [Internet].
2018 Jan 1 [cited 2019 Nov 16];192:223-228.e1.
11. Rudders S, Banerji A, Clark S, Camargo CJ. Age-related differences
in the clinical presentation of food-induced anaphylaxis. J Pediatr.
2011;58(2):326–8.
12. Tejedor Alonso MA, Moro-Moro M, Mugica Garcia MV. Epidemiology of
anaphylaxis. Clin Exp Allergy. 2015;45:1027–1039.
13. Jeon YH, Ahn K, et al. Infantile Anaphylaxis in Korea: a Multicenter
Retrospective Case Study. J Korean Med Sci. 2019;34(13):e10.
14. Sicherer SH, Furlong TJ, Muñoz-Furlong A, Burks AW, Sampson HA. A
voluntary registry for peanut and tree nut allergy: Characteristics of
the first 5149 registrants. J Allergy Clin Immunol. 2001;108(1):128–32.
15. Gupta RS, Warren CM, Smith BM, Blumenstock JA, Jiang J, Davis MM, et
al. The public health impact of parent-reported childhood food allergies
in the United States. Pediatrics. 2018;142(6).
16. Wölbing F, Fischer J, Köberle M, Kaesler S, Biedermann T. About the
role and underlying mechanisms of cofactors in anaphylaxis. Vol. 68,
Allergy: European Journal of Allergy and Clinical Immunology. 2013. p.
1085–92.
17. Hompes S, Köhli A, Nemat K, Scherer K, Lange L, Rueff F, et al.
Provoking allergens and treatment of anaphylaxis in children and
adolescents - data from the anaphylaxis registry of German-speaking
countries. Pediatr Allergy Immunol. 2011;22(6):568–74.
18. Robertson ON, Hourihane JO, Remington BC, Baumert JL, Taylor SL.
Survey of peanut levels in selected Irish food products bearing peanut
allergen advisory labels. Food Addit Contam Part A [Internet]. 2013
Sep [cited 2019 Nov 16];30(9):1467–72.
19. Ford LS, Taylor SL, Pacenza R, Niemann LM, Lambrecht DM, Sicherer
SH. Food allergen advisory labeling and product contamination with egg,
milk, and peanut. J Allergy Clin Immunol [Internet]. 2010 Aug 1
[cited 2019 Nov 16];126(2):384–5.
20. Blom WM, Michelsen-Huisman AD, van Os-Medendorp H, van Duijn G, de
Zeeuw-Brouwer M lène, Versluis A, et al. Accidental food allergy
reactions: Products and undeclared ingredients. J Allergy Clin Immunol.
2018;142(3):865–75.
21. Worm M, Moneret-Vautrin A, Scherer K, Lang R, Fernandez-Rivas M,
Cardona V, et al. First European data from the network of severe
allergic reactions (NORA). Allergy Eur J Allergy Clin Immunol.
2014;69(10):1397–404.
22. Orhan F, Canitez Y, Bakirtas A, Yilmaz O, et al. Anaphylaxis in
Turkish children: a multi-centre, retrospective, case study. Clin Exp
Allergy. 2011;41(12):1767–76.
23. Alqurashi W, Stiell I, Chan K, Neto G, Alsadoon A, Wells G.
Epidemiology and clinical predictors of biphasic reactions in children
with anaphylaxis. Ann Allergy, Asthma Immunol. 2015;115(3).
24. Lee S, Bellolio MF, Hess EP, Erwin P, Murad MH, Campbell RL. Time of
Onset and Predictors of Biphasic Anaphylactic Reactions: A Systematic
Review and Meta-analysis. J Allergy Clin Immunol Pract. 2015;3(3).
25. Gaziel Yablowitz M, Dölle S, Schwartz DG, Worm M. Proximity-Based
Emergency Response Communities for Patients With Allergies Who Are at
Risk of Anaphylaxis: Clustering Analysis and Scenario-Based Survey
Study. JMIR mHealth uHealth. 2019;7(8):e13414.
26. Simons FER, Clark S, Camargo CA. Anaphylaxis in the community:
Learning from the survivors. J Allergy Clin Immunol [Internet]. 2009
Aug 1 [cited 2019 Nov 16];124(2):301–6.
27. Grabenhenrich LB, Fernández-Rivas M, Dölle-Bierke S, Worm M.
Repeated epinephrine doses: An analysis of the European Anaphylaxis
Registry, 2007-2018. J Allergy Clin Immunol Pract [Internet]. 2019
Nov 1 [cited 2019 Nov 16];7(8):2935–7.
28. Grossman SL, Baumann BM, Garcia Peña BM, Linares MY-R, Greenberg B,
Hernandez-Trujillo VP. Anaphylaxis knowledge and practice preferences of
pediatric emergency medicine physicians: a national survey. J Pediatr
[Internet]. 2013 Sep 1 [cited 2019 Nov 16];163(3):841–6.
29. Michelson KA, Monuteaux MC, Neuman MI. Variation and Trends in
Anaphylaxis Care in United States Children’s Hospitals. Vol. 23,
Academic Emergency Medicine. 2016. p. 623–7.
30. Manivannan V, Campbell RL, Bellolio MF, Stead LG, Li JT, Decker W.
Factors associated with repeated use of epinephrine for the treatment of
anaphylaxis. Ann Allergy Asthma Immunol. 2009;103(5):395‐400.